The FDA has approved Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback